November 2, 2024 Tech Titans’ Mixed Results Stall Wall Street Bull Run
October 28, 2024 Recent Oil Slides In Global Markets, Japan In Flux
Microsoft: The Party Is Coming To An End
Apple Q4: Further Risk To Near-Term China Estimate?
Apple: Berkshire Sales And Slow Revenue Raise Concerns
AMZN: Wall Street’s Most Loved Stock May Be A Growth Trap
October 22, 2024 A Comprehensive Guide to RoadRunner Auto Transport Services
October 3, 2024 Mastering Trading Indicators: Your Essential Toolkit For Success
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
April 12, 2024 Improve Your Financial Status: A How-To Guide
NLS Pharmaceutics (NLSP) stock forecast for 2026
Updated: November 6, 2024 (06:16)
Sector: HealthcareThe share price of NLS Pharmaceutics AG (NLSP) now
50/200 Day Moving Average: $5.17 / $8.43
This figure corresponds to the Average Price over the previous 50/200 days. For NLS Pharmaceutics stocks, the 50-day moving average is the resistance level today.
For NLS Pharmaceutics stocks, the 200-day moving average is the resistance level today.
Are you interested in NLS Pharmaceutics AG stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the NLS Pharmaceutics stock price in 2026. How much will one NLS Pharmaceutics share be worth in 2026? Is it worth taking profit / loss on NLSP stock now or waiting? What are analysts' forecasts for NLS Pharmaceutics stock?
We forecast NLS Pharmaceutics stock performance using neural networks based on historical data on NLSP stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.
NLS Pharmaceutics AG stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for NLS Pharmaceutics analysts is $6. Today 200 Day Moving Average is the resistance level (8.43 $). 50 Day Moving Average is the resistance level (5.17 $).
Historical and forecast chart of NLS Pharmaceutics AG stock
The chart below shows the historical price of NLS Pharmaceutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the NLSP stock price can be found in the table below.
NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder. The company was founded by Ronald Hafner and Alexander Zwyer in June 2015 and is headquartered in Stans, Switzerland.
NLS Pharmaceutics (NLSP) Forecast for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 2.26 | 2.19 | 2.46 | 10.87 % |
Feb | 2.26 | 2.08 | 2.47 | 15.49 % |
Mar | 2.31 | 2.21 | 2.49 | 10.97 % |
Apr | 2.42 | 2.34 | 2.50 | 6.16 % |
May | 2.35 | 2.17 | 2.42 | 10.22 % |
Jun | 2.54 | 2.46 | 2.79 | 11.83 % |
Jul | 2.26 | 2.04 | 2.37 | 13.64 % |
Aug | 2.13 | 1.92 | 2.30 | 16.60 % |
Sep | 2.05 | 1.87 | 2.20 | 14.99 % |
Oct | 2.11 | 1.90 | 2.25 | 15.46 % |
Nov | 2.01 | 1.90 | 2.20 | 13.42 % |
Dec | 2.13 | 2.02 | 2.25 | 10.19 % |
NLS Pharmaceutics information and performance
ALTER POSTPLATZ 2, STANS, CH
Market capitalization of the NLS Pharmaceutics AG is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of NLSP shares in the company outstanding by the market price of one share.
EBITDA of NLS Pharmaceutics is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
NLS Pharmaceutics price target for 2026 by month
Target values for the price of one NLS Pharmaceutics share for Jan 2026.
In Jan, the Negative dynamics for NLS Pharmaceutics AG shares will prevail with possible monthly volatility of 10.869% volatility is expected.
Pessimistic target level: 2.19
Optimistic target level: 2.46
Target values for the price of one NLS Pharmaceutics share for Feb 2026.
In Feb, the Negative dynamics for NLS Pharmaceutics AG shares will prevail with possible monthly volatility of 15.490% volatility is expected.
Pessimistic target level: 2.08
Optimistic target level: 2.47
Target values for the price of one NLS Pharmaceutics share for Mar 2026.
In Mar, the Positive dynamics for NLS Pharmaceutics AG shares will prevail with possible monthly volatility of 10.974% volatility is expected.
Pessimistic target level: 2.21
Optimistic target level: 2.49
Target values for the price of one NLS Pharmaceutics share for Apr 2026.
In Apr, the Positive dynamics for NLS Pharmaceutics AG shares will prevail with possible monthly volatility of 6.162% volatility is expected.
Pessimistic target level: 2.34
Optimistic target level: 2.50
Target values for the price of one NLS Pharmaceutics share for May 2026.
In May, the Negative dynamics for NLS Pharmaceutics AG shares will prevail with possible monthly volatility of 10.224% volatility is expected.
Pessimistic target level: 2.17
Optimistic target level: 2.42
Target values for the price of one NLS Pharmaceutics share for Jun 2026.
In Jun, the Positive dynamics for NLS Pharmaceutics AG shares will prevail with possible monthly volatility of 11.831% volatility is expected.
Pessimistic target level: 2.46
Optimistic target level: 2.79
Target values for the price of one NLS Pharmaceutics share for Jul 2026.
In Jul, the Negative dynamics for NLS Pharmaceutics AG shares will prevail with possible monthly volatility of 13.644% volatility is expected.
Pessimistic target level: 2.04
Optimistic target level: 2.37
Target values for the price of one NLS Pharmaceutics share for Aug 2026.
In Aug, the Negative dynamics for NLS Pharmaceutics AG shares will prevail with possible monthly volatility of 16.602% volatility is expected.
Pessimistic target level: 1.92
Optimistic target level: 2.30
Target values for the price of one NLS Pharmaceutics share for Sep 2026.
In Sep, the Negative dynamics for NLS Pharmaceutics AG shares will prevail with possible monthly volatility of 14.990% volatility is expected.
Pessimistic target level: 1.87
Optimistic target level: 2.20
Target values for the price of one NLS Pharmaceutics share for Oct 2026.
In Oct, the Positive dynamics for NLS Pharmaceutics AG shares will prevail with possible monthly volatility of 15.465% volatility is expected.
Pessimistic target level: 1.90
Optimistic target level: 2.25
Target values for the price of one NLS Pharmaceutics share for Nov 2026.
In Nov, the Negative dynamics for NLS Pharmaceutics AG shares will prevail with possible monthly volatility of 13.417% volatility is expected.
Pessimistic target level: 1.90
Optimistic target level: 2.20
Target values for the price of one NLS Pharmaceutics share for Dec 2026.
In Dec, the Positive dynamics for NLS Pharmaceutics AG shares will prevail with possible monthly volatility of 10.193% volatility is expected.
Pessimistic target level: 2.02
Optimistic target level: 2.25
Related stocks from Healthcare sector